Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis.

Cook LM, Frieling JS, Nerlakanti N, McGuire JJ, Stewart PA, Burger KL, Cleveland JL, Lynch CC.

Oncogene. 2019 Aug 13. doi: 10.1038/s41388-019-0913-4. [Epub ahead of print]

PMID:
31409900
2.

Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC).

Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L.

Leuk Res. 2019 Sep;84:106194. doi: 10.1016/j.leukres.2019.106194. Epub 2019 Jul 18.

PMID:
31357093
3.

African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.

Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K.

J Urol. 2019 Aug;202(2):247-255. doi: 10.1097/JU.0000000000000193. Epub 2019 Jul 8.

PMID:
31107158
4.

BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models.

Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, Koomen JM, Jiang H, Sudalagunta PR, Meads MB, Cheng F, Bi C, Fu K, Fan H, Dalton WS, Moscinski LC, Shain KH, Sotomayor EM, Wang GG, Gray NS, Cleveland JL, Qi J, Tao J.

Cancer Cell. 2019 May 13;35(5):752-766.e9. doi: 10.1016/j.ccell.2019.04.005.

PMID:
31085176
5.

S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes.

Cheng P, Eksioglu EA, Chen X, Kandell W, Le Trinh T, Cen L, Qi J, Sallman DA, Zhang Y, Tu N, Adams WA, Zhang C, Liu J, Cleveland JL, List AF, Wei S.

Leukemia. 2019 Aug;33(8):2034-2046. doi: 10.1038/s41375-019-0397-9. Epub 2019 Feb 8.

6.

Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.

Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, Cleveland JL, Park JY, Dhillon J, Yamoah K.

Prostate Cancer Prostatic Dis. 2019 May;22(2):292-302. doi: 10.1038/s41391-018-0103-4. Epub 2018 Oct 26.

PMID:
30367117
7.

ATF4-amino acid circuits: a recipe for resistance in melanoma.

Fernandez MR, Cleveland JL.

EMBO J. 2018 Oct 15;37(20). pii: e100600. doi: 10.15252/embj.2018100600. Epub 2018 Sep 28. No abstract available.

PMID:
30266826
8.

PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.

Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, Silva AS, Shah BD, Fang B, Li T, Koomen JM, Jiang H, Chavez JC, Pham LV, Sudalagunta PR, Wan L, Wang X, Dalton WS, Moscinski LC, Shain KH, Vose J, Cleveland JL, Sotomayor EM, Fu K, Tao J.

J Clin Invest. 2018 Dec 3;128(12):5517-5530. doi: 10.1172/JCI122533. Epub 2018 Nov 5.

9.

Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.

Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K.

Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1376-1383. doi: 10.1158/1055-9965.EPI-18-0369. Epub 2018 Aug 14.

PMID:
30108099
10.

P450-Catalyzed Tailoring Steps in Leinamycin Biosynthesis Featuring Regio- and Stereoselective Hydroxylations and Substrate Promiscuities.

Kwong T, Ma M, Pan G, Hindra, Yang D, Yang C, Lohman JR, Rudolf JD, Cleveland JL, Shen B.

Biochemistry. 2018 Aug 21;57(33):5005-5013. doi: 10.1021/acs.biochem.8b00623. Epub 2018 Aug 2.

11.

Systems analysis of intracellular pH vulnerabilities for cancer therapy.

Persi E, Duran-Frigola M, Damaghi M, Roush WR, Aloy P, Cleveland JL, Gillies RJ, Ruppin E.

Nat Commun. 2018 Jul 31;9(1):2997. doi: 10.1038/s41467-018-05261-x.

12.

Implementation to Optimization: A Tailored, Data-Driven Approach to Improve Provider Efficiency and Confidence in Use of the Electronic Medical Record.

Kadish SS, Mayer EL, Jackman DM, Pomerantz M, Brady L, Dimitriadis A, Cleveland JLF, Wagner AJ.

J Oncol Pract. 2018 Jul;14(7):e421-e428. doi: 10.1200/JOP.18.00093. Epub 2018 Jun 25.

PMID:
29939808
13.

Distinct Immunomodulatory Effects of Spermine Oxidase in Colitis Induced by Epithelial Injury or Infection.

Gobert AP, Al-Greene NT, Singh K, Coburn LA, Sierra JC, Verriere TG, Luis PB, Schneider C, Asim M, Allaman MM, Barry DP, Cleveland JL, Destefano Shields CE, Casero RA Jr, Washington MK, Piazuelo MB, Wilson KT.

Front Immunol. 2018 Jun 5;9:1242. doi: 10.3389/fimmu.2018.01242. eCollection 2018.

14.

Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses.

Singh K, Coburn LA, Asim M, Barry DP, Allaman MM, Shi C, Washington MK, Luis PB, Schneider C, Delgado AG, Piazuelo MB, Cleveland JL, Gobert AP, Wilson KT.

Cancer Res. 2018 Aug 1;78(15):4303-4315. doi: 10.1158/0008-5472.CAN-18-0116. Epub 2018 May 31.

15.

MDMX acidic domain inhibits p53 DNA binding in vivo and regulates tumorigenesis.

Huang Q, Chen L, Yang L, Xie X, Gan L, Cleveland JL, Chen J.

Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3368-E3377. doi: 10.1073/pnas.1719090115. Epub 2018 Mar 26.

16.

Role of Polyamines in Immune Cell Functions.

Hesterberg RS, Cleveland JL, Epling-Burnette PK.

Med Sci (Basel). 2018 Mar 8;6(1). pii: E22. doi: 10.3390/medsci6010022. Review.

17.

Metabolic Reprogramming via Targeting CD38 NADase Augments Adoptive T Cell Therapy.

Fernandez MR, Cleveland JL.

Cell Metab. 2018 Jan 9;27(1):3-5. doi: 10.1016/j.cmet.2017.12.014.

18.

Activation of endoplasmic reticulum stress response by enhanced polyamine catabolism is important in the mediation of cisplatin-induced acute kidney injury.

Zahedi K, Barone S, Destefano-Shields C, Brooks M, Murray-Stewart T, Dunworth M, Li W, Doherty JR, Hall MA, Smith RD, Cleveland JL, Casero RA Jr, Soleimani M.

PLoS One. 2017 Sep 8;12(9):e0184570. doi: 10.1371/journal.pone.0184570. eCollection 2017.

19.

Ornithine decarboxylase regulates M1 macrophage activation and mucosal inflammation via histone modifications.

Hardbower DM, Asim M, Luis PB, Singh K, Barry DP, Yang C, Steeves MA, Cleveland JL, Schneider C, Piazuelo MB, Gobert AP, Wilson KT.

Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):E751-E760. doi: 10.1073/pnas.1614958114. Epub 2017 Jan 17.

20.

CK1δ: an exploitable vulnerability in breast cancer.

Rosenberg LH, Cleveland JL, Roush WR, Duckett DR.

Ann Transl Med. 2016 Dec;4(23):474. doi: 10.21037/atm.2016.12.15. No abstract available.

21.

Lactate Wreaks Havoc on Tumor-Infiltrating T and NK Cells.

Scott KE, Cleveland JL.

Cell Metab. 2016 Nov 8;24(5):649-650. doi: 10.1016/j.cmet.2016.10.015.

22.

Tristetraprolin disables prostate cancer maintenance by impairing proliferation and metabolic function.

Berglund AE, Scott KE, Li W, Yang C, Fernandez MR, Schaub FX, Cleveland JL, Rounbehler RJ.

Oncotarget. 2016 Dec 13;7(50):83462-83475. doi: 10.18632/oncotarget.13128.

23.

Functional Roles of Acetylated Histone Marks at Mouse Meiotic Recombination Hot Spots.

Getun IV, Wu Z, Fallahi M, Ouizem S, Liu Q, Li W, Costi R, Roush WR, Cleveland JL, Bois PRJ.

Mol Cell Biol. 2017 Jan 19;37(3). pii: e00942-15. doi: 10.1128/MCB.00942-15. Print 2017 Feb 1.

24.

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF.

Blood. 2016 Dec 22;128(25):2960-2975. doi: 10.1182/blood-2016-07-730556. Epub 2016 Oct 13.

25.

Targeting the polyamine-hypusine circuit for the prevention and treatment of cancer.

Nakanishi S, Cleveland JL.

Amino Acids. 2016 Oct;48(10):2353-62. doi: 10.1007/s00726-016-2275-3. Epub 2016 Jun 29. Review.

26.

Exploiting the co-reliance of tumours upon transport of amino acids and lactate: Gln and Tyr conjugates of MCT1 inhibitors.

Nair RN, Mishra JK, Li F, Tortosa M, Yang C, Doherty JR, Cameron M, Cleveland JL, Roush WR, Bannister TD.

Medchemcomm. 2016 May 1;7(5):900-905. Epub 2016 Feb 23.

27.

Transmission of blood-borne pathogens in US dental health care settings: 2016 update.

Cleveland JL, Gray SK, Harte JA, Robison VA, Moorman AC, Gooch BF.

J Am Dent Assoc. 2016 Sep;147(9):729-38. doi: 10.1016/j.adaj.2016.03.020. Epub 2016 May 24.

28.

Synthesis and Cytoxicity of Sempervirine and Analogues.

Pan X, Yang C, Cleveland JL, Bannister TD.

J Org Chem. 2016 Mar 4;81(5):2194-200. doi: 10.1021/acs.joc.6b00022. Epub 2016 Feb 10.

29.

Therapeutic targeting of casein kinase 1δ in breast cancer.

Rosenberg LH, Lafitte M, Quereda V, Grant W, Chen W, Bibian M, Noguchi Y, Fallahi M, Yang C, Chang JC, Roush WR, Cleveland JL, Duckett DR.

Sci Transl Med. 2015 Dec 16;7(318):318ra202. doi: 10.1126/scitranslmed.aac8773.

30.

Fluorophore-NanoLuc BRET Reporters Enable Sensitive In Vivo Optical Imaging and Flow Cytometry for Monitoring Tumorigenesis.

Schaub FX, Reza MS, Flaveny CA, Li W, Musicant AM, Hoxha S, Guo M, Cleveland JL, Amelio AL.

Cancer Res. 2015 Dec 1;75(23):5023-33. doi: 10.1158/0008-5472.CAN-14-3538. Epub 2015 Sep 30.

31.

Development of an HTS-Compatible Assay for the Discovery of Ulk1 Inhibitors.

Rosenberg LH, Lafitte M, Grant W, Chen W, Cleveland JL, Duckett DR.

J Biomol Screen. 2015 Aug;20(7):913-20. doi: 10.1177/1087057115579391. Epub 2015 Apr 7.

32.

Hrr25/CK1δ-directed release of Ltv1 from pre-40S ribosomes is necessary for ribosome assembly and cell growth.

Ghalei H, Schaub FX, Doherty JR, Noguchi Y, Roush WR, Cleveland JL, Stroupe ME, Karbstein K.

J Cell Biol. 2015 Mar 16;208(6):745-59. doi: 10.1083/jcb.201409056.

33.

CREB targets define the gene expression signature of malignancies having reduced levels of the tumor suppressor tristetraprolin.

Fallahi M, Amelio AL, Cleveland JL, Rounbehler RJ.

PLoS One. 2014 Dec 26;9(12):e115517. doi: 10.1371/journal.pone.0115517. eCollection 2014.

34.

Tipping the MYC-MIZ1 balance: targeting the HUWE1 ubiquitin ligase selectively blocks MYC-activated genes.

Schaub FX, Cleveland JL.

EMBO Mol Med. 2014 Dec;6(12):1509-11. doi: 10.15252/emmm.201404735.

35.

Embryonic Expression and Function of the Xenopus Ink4d Cyclin D-Dependent Kinase Inhibitor.

Doherty JR, Nilsson LM, Kuliyev E, Zhu H, Matthew R, Cleveland JL, Mead PE, Roussel MF.

Cell Dev Biol. 2014 Feb 15;3(1). pii: 133.

36.

Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.

Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, Laitinen I, Nilsson L, Goga A, Peschel C, Nilsson JA, Cleveland JL, Keller U.

Blood. 2014 Sep 25;124(13):2081-90. doi: 10.1182/blood-2014-06-584524. Epub 2014 Aug 20.

37.

CRTC1/MAML2 gain-of-function interactions with MYC create a gene signature predictive of cancers with CREB-MYC involvement.

Amelio AL, Fallahi M, Schaub FX, Zhang M, Lawani MB, Alperstein AS, Southern MR, Young BM, Wu L, Zajac-Kaye M, Kaye FJ, Cleveland JL, Conkright MD.

Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):E3260-8. doi: 10.1073/pnas.1319176111. Epub 2014 Jul 28.

38.

Synthesis and structure-activity relationships of pteridine dione and trione monocarboxylate transporter 1 inhibitors.

Wang H, Yang C, Doherty JR, Roush WR, Cleveland JL, Bannister TD.

J Med Chem. 2014 Sep 11;57(17):7317-24. doi: 10.1021/jm500640x. Epub 2014 Aug 22.

39.

Human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States.

Steinau M, Saraiya M, Goodman MT, Peters ES, Watson M, Cleveland JL, Lynch CF, Wilkinson EJ, Hernandez BY, Copeland G, Saber MS, Hopenhayn C, Huang Y, Cozen W, Lyu C, Unger ER; HPV Typing of Cancers Workgroup.

Emerg Infect Dis. 2014 May;20(5):822-8. doi: 10.3201/eid2005.131311.

40.

Synthesis of C11-Desmethoxy Soraphen A: A natural product analog that inhibits acetyl-CoA carboxylase.

Canterbury DP, Scott KE, Kubo O, Jansen R, Cleveland JL, Micalizio GC.

ACS Med Chem Lett. 2013 Dec 12;4(12):1244-1248.

41.

CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis.

Lu Y, Wu Y, Feng X, Shen R, Wang JH, Fallahi M, Li W, Yang C, Hankey W, Zhao W, Ganju RK, Li MO, Cleveland JL, Zou X.

J Clin Invest. 2014 Apr;124(4):1672-84. doi: 10.1172/JCI63139. Epub 2014 Mar 10.

42.

Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.

Doherty JR, Yang C, Scott KE, Cameron MD, Fallahi M, Li W, Hall MA, Amelio AL, Mishra JK, Li F, Tortosa M, Genau HM, Rounbehler RJ, Lu Y, Dang CV, Kumar KG, Butler AA, Bannister TD, Hooper AT, Unsal-Kacmaz K, Roush WR, Cleveland JL.

Cancer Res. 2014 Feb 1;74(3):908-20. doi: 10.1158/0008-5472.CAN-13-2034. Epub 2013 Nov 27.

43.

Clinical oral examinations may not be predictive of dysplasia or oral squamous cell carcinoma.

Cleveland JL, Robison VA.

J Evid Based Dent Pract. 2013 Dec;13(4):151-4. doi: 10.1016/j.jebdp.2013.10.006. Epub 2013 Oct 11. No abstract available.

44.

Hepatitis B virus transmissions associated with a portable dental clinic, West Virginia, 2009.

Radcliffe RA, Bixler D, Moorman A, Hogan VA, Greenfield VS, Gaviria DM, Patel PR, Schaefer MK, Collins AS, Khudyakov YE, Drobeniuc J, Gooch BF, Cleveland JL.

J Am Dent Assoc. 2013;144(10):1110-8. Erratum in: J Am Dent Assoc. 2013 Nov;144(11):1228.

45.

Targeting lactate metabolism for cancer therapeutics.

Doherty JR, Cleveland JL.

J Clin Invest. 2013 Sep;123(9):3685-92. doi: 10.1172/JCI69741. Epub 2013 Sep 3. Review.

46.

Development of highly selective casein kinase 1δ/1ε (CK1δ/ε) inhibitors with potent antiproliferative properties.

Bibian M, Rahaim RJ, Choi JY, Noguchi Y, Schürer S, Chen W, Nakanishi S, Licht K, Rosenberg LH, Li L, Feng Y, Cameron MD, Duckett DR, Cleveland JL, Roush WR.

Bioorg Med Chem Lett. 2013 Aug 1;23(15):4374-80. doi: 10.1016/j.bmcl.2013.05.075. Epub 2013 May 31.

47.

Synthesis and SAR of Lehualide B: a marine-derived natural product with potent anti-multiple myeloma activity.

Jeso V, Yang C, Cameron MD, Cleveland JL, Micalizio GC.

ACS Chem Biol. 2013;8(6):1241-52. doi: 10.1021/cb300582s. Epub 2013 Apr 2.

48.

Advancing infection control in dental care settings: factors associated with dentists' implementation of guidelines from the Centers for Disease Control and Prevention.

Cleveland JL, Bonito AJ, Corley TJ, Foster M, Barker L, Gordon Brown G, Lenfestey N, Lux L.

J Am Dent Assoc. 2012 Oct;143(10):1127-38. Erratum in: J Am Dent Assoc. 2012 Dec;143(12):1289.

49.

Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state.

Rounbehler RJ, Fallahi M, Yang C, Steeves MA, Li W, Doherty JR, Schaub FX, Sanduja S, Dixon DA, Blackshear PJ, Cleveland JL.

Cell. 2012 Aug 3;150(3):563-74. doi: 10.1016/j.cell.2012.06.033.

50.

Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas.

Rethman MP, Carpenter W, Cohen EE, Epstein J, Evans CA, Flaitz CM, Graham FJ, Hujoel PP, Kalmar JR, Koch WM, Lambert PM, Lingen MW, Oettmeier BW Jr, Patton LL, Perkins D, Reid BC, Sciubba JJ, Tomar SL, Wyatt AD Jr, Aravamudhan K, Frantsve-Hawley J, Cleveland JL, Meyer DM; American Dental Association Council on Scientific Affairs Expert Panel on Screening for Oral Souamous Cell Carcinomas.

Tex Dent J. 2012 May;129(5):491-507.

PMID:
22779205

Supplemental Content

Loading ...
Support Center